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MaMost cardiomyopathies are familial diseases. Cascade family screening identiﬁes asymptomatic patients and family
members with early traits of disease. The inheritance is autosomal dominant in a majority of cases, and recessive,
X-linked, or matrilinear in the remaining. For the last 50 years, cardiomyopathy classiﬁcations have been based on the
morphofunctional phenotypes, allowing cardiologists to conveniently group them in broad descriptive categories.
However, the phenotype may not always conform to the genetic characteristics, may not allow risk stratiﬁcation, and may
not provide pre-clinical diagnoses in the family members. Because genetic testing is now increasingly becoming a part of
clinical work-up, and based on the genetic heterogeneity, numerous new names are being coined for the description of
cardiomyopathies associated with mutations in different genes; a comprehensive nosology is needed that could inform
the clinical phenotype and involvement of organs other than the heart, as well as the genotype and the mode of
inheritance. The recently proposed MOGE(S) nosology system embodies all of these characteristics, and describes the
morphofunctional phenotype (M), organ(s) involvement (O), genetic inheritance pattern (G), etiological annotation (E)
including genetic defect or underlying disease/substrate, and the functional status (S) of the disease using both the
American College of Cardiology/American Heart Association stage and New York Heart Association functional class. The
proposed nomenclature is supported by a web-assisted application and assists in the description of cardiomyopathy in
symptomatic or asymptomatic patients and family members in the context of genetic testing. It is expected that such a
nomenclature would help group cardiomyopathies on their etiological basis, describe complex genetics, and create
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ABB R E V I A T I O N S
AND ACRONYMS
ACC = American College of
Cardiology
AHA = American Heart
Association
ARVC = arrhythmogenic right
ventricular cardiomyopathy
AVB = atrioventricular block
DCM = dilated cardiomyopathy
EMF = endomyocardial ﬁbrosis
HCM = hypertrophic
cardiomyopathy
LV = left ventricle
LVNC = left ventricular
noncompaction
RCM = restrictive
cardiomyopathy
WPW = Wolff-Parkinson-White
syndrome
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305each major type of cardiomyopathy into familial or
genetic, and nonfamilial or nongenetic forms (1,2).
The American College of Cardiology (ACC)/AHA stag-
ing of the heart failure (HF) included asymptomatic
patients with a familial history of cardiomyopathy in
the stage A or pre-HF (3).
In the last 20 years, the systematic approach to
family screening has contributed to better assess-
ment of familial cardiomyopathies. This method has
allowed the identiﬁcation of family members who are
predisposed to disease development, based on the in-
heritance of the cardiomyopathy-associated gene(s).
The electrocardiographic and echocardiographic clues
may show early (subclinical) cardiac involvement
(4–10). On the other hand, the nongenetic cardiomy-
opathies may be described as associated with speciﬁc
etiologies, such as viral infections, autoimmune dis-
eases, and endogenous or exogenous myocardial
toxicity. The contemporary diagnostic algorithms
for work-up of cardiomyopathies are supported by
advanced imaging characterization, disease-speciﬁc
biomarkers, and genetic analyses (11). The number of
cardiomyopathies wherein the cause is identiﬁed (or
identiﬁable) is increasing, supported by the family
screening and follow up for segregation studies of
genotype with phenotype.
The morphofunctional phenotype-based classiﬁ-
cation of cardiomyopathies continues to offer cardi-
ologists the possibility of using a simple and clinically
useful diagnostic language (Table 1). All treatment
protocols are currently based on the phenotype, as
well as signs and symptoms. The phenotype-based
classiﬁcation (hypertrophic cardiomyopathy [HCM],
dilated cardiomyopathy [DCM], restrictive cardiomy-
opathy [RCM], arrhythmogenic right ventricular car-
diomyopathy [ARVC]/arrhythmogenic ventricular
cardiomyopathy, and left ventricular noncompaction
[LVNC]) describes the major forms of cardiomyopa-
thy, but not their causes. However, cardiomyopathies
are clinically heterogeneous diseases (12–17), and
within each subtype of cardiomyopathy there are
differences in sex, age of onset, rate of progression,
risk of development of overt heart failure, and like-
lihood of sudden death. In the DCM group, for
example, there are patients with mildly enlarged
and mildly dysfunctional left ventricle (LV) that
develop life-threatening ventricular arrhythmias;
yet, there may be patients with extremely dilated
and dysfunctional LV but low arrhythmogenic risk.
Similarly, in the HCM group, there are patients with
severe left ventricular hypertrophy who are asymp-
tomatic and do not demonstrate life-threatening ar-
rhythmias. Finally, there are patients who show mild
to moderate hypertrophy but carry a high risk ofarrhythmias. Numerous electrocardiographic
markers have been shown to be associated
with cardiomyopathy in a subset of the
patients, including atrioventricular block
(AVB), pre-excitation syndrome (Wolff-Par-
kinson-White syndrome [WPW]), repolariza-
tion abnormalities, or low QRS voltage.
Echocardiography and cardiac magnetic reso-
nance imaging may reveal variable features
within the similar phenotypes, including the
severity, distribution, and extent of myocar-
dial hypertrophy, thickening of valves, non-
compaction, ventricular dilation, ventricular
dysfunction, myocardial ﬁbrosis, inﬁltrative
or intramyocyte storage, or fatty inﬁltration of
the myocardium (18,19). Although each sub-
type of cardiomyopathy is deﬁned by its major
morphofunctional phenotype, a careful clin-
ical evaluation demonstrates high phenotype
variability.Most cardiomyopathies demonstrate an auto-
somal dominant inheritance, but X-linked recessive,
autosomal recessive, or matrilineal inheritance may
occur in a minority of cases. Although elucidation
of family history and comprehensive assessment
of pedigree is the foremost necessity in family
studies (17,20,21), it may not be by itself sufﬁcient
to establish the diagnosis of familial cardiomyo-
pathy. Cascade family screening and monitoring
may be necessary to identify affected but asymp-
tomatic family members unaware of their disease,
or who display subclinical abnormalities by non-
invasive imaging tests as early markers of the
disease (16,17).
The knowledge of the genetic basis of all kinds
of cardiomyopathies has progressively increased
(12–14,22). Linkage analyses (23), genome-wide asso-
ciation studies (GWAS) (24,25), and whole-exome se-
quencing (WES) (26) have incrementally contributed
to the list of disease genes (Online Table 1), which
now includes more than 100 genes. HCM is caused by
the mutations of genes that code for structural and
functional proteins of the sarcomere (15), whereas
DCM is caused by the mutation of genes related to
structure and function of nuclear envelope, cyto-
skeleton, sarcomere, and sarcoplasmic reticulum (27).
ARVC is known as a collection of diseases of the
desmosome (28), and RCM is caused by defects in
genes encoding for sarcomeric proteins (29) or inter-
mediate ﬁlaments, such as desmin (20).
However, the early assignment of phenotypes to
groups of genes and pathways is no longer conﬁrmed
by recent genetic studies. In fact, genes may cause
similar phenotypes (Fig. 1), most disease genes are not
TABLE 1 Recapitulation of the Classiﬁcation Systems for Cardiomyopathies in the
Last 50 Years
Year Deﬁnitions/Classiﬁcations References
1956 Myocardial diseases classiﬁed as
myocarditis (inﬂammatory heart
muscle disease), and myocardiosis
(other heart muscle diseases).
Blankerhorn and Gall (71)
1957 The term cardiomyopathy proposed for
uncommon, noncoronary heart muscle
diseases.
Bridgen (72)
1972 Cardiomyopathy described as myocardial
diseases of unknown origin, and ﬁrst
classiﬁcation proposed as dilated,
hypertrophic, and restrictive (or
obliterative) cardiomyopathy.
Goodwin and Oakley (73)
1980 WHO-ISFC adopts Goodwin and Oakley
classiﬁcation, and deﬁnes
cardiomyopathies as myocardial
diseases of unknown etiology. WHO-
ISFC adds speciﬁc heart muscle
diseases (cause of myocardial
afﬂiction known) to the classiﬁcation.
Report of the WHO/ISFC Task Force on
the Deﬁnition and Classiﬁcation of
Cardiomyopathies (74)
1996 WHO-ISFC updates its classiﬁcation of
cardiomyopathies (diseases of
myocardium associated with
myocardial dysfunction). The update
includes arrhythmogenic right
ventricular cardiomyopathy and
unclassiﬁed cardiomyopathy, but
excludes speciﬁc heart muscle
disease.
Richardson et al. (75)
1998 ISFC becomes WHF
2006 AHA deﬁnes cardiomyopathies as
diseases of myocardium associated
with mechanical and/or electrical
dysfunction, which usually (but not
invariably) exhibit inappropriate
ventricular hypertrophy or dilation,
due to a variety of causes that
frequently are genetic, classiﬁed as
primary or secondary. Presents ﬁrst
visionary attempt to classify primary
cardiomyopathy by genetic origin
(genetic, acquired, or mixed)
Maron et al. (1)
2008 ESC deﬁnes cardiomyopathies as
myocardial disorder in which the heart
muscle was structurally and
functionally abnormal. Classiﬁed
dilated, hypertrophic, restrictive,
arrhythmogenic right ventricular, or
unclassiﬁed cardiomyopathy
subtypes as familial/genetic and
nonfamilial/nongenetic. Maintained
the importance of phenotype
preceding genetic classiﬁcation for
clinical practice.
Elliott et al. (2)
2013 WHF-MOGE(S) nosology proposes a
descriptive genotype-phenotype
nosology system.
Arbustini et al. (54,55)
AHA ¼ American Heart Association; ESC ¼ European Society of Cardiology; ISFC ¼ International Society and
Federation of Cardiology; WHF ¼ World Heart Federation; WHO ¼ World Health Organization.
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306linked to a unique phenotype, and identical gene
mutations may result in different phenotypes (Fig. 2).
For instance, sarcomeric gene defects associated with
HCM also may result in DCM (30), and desmosome
genes coupled with ARVC may cause DCM (31). Genes
encoding intermediate ﬁlaments, such as nuclear
lamins, in addition to DCM may cause ARVC (32), andnonsarcomeric genes also may cause HCM (33). An
increasing number of cardiomyopathies are being
recognized as associated with complex genetics (34).
More than 100 nuclear and mitochondrial disease-
causing genes have been identiﬁed encoding for the
proteins of nuclear envelope, sarcolemma, cytoskel-
eton, sarcomere, or desmosome, or those involved in
calcium-handling and energy production (Online
Table 1). The constantly increasing number of
disease-causing genes suggests that the unresolved
issue of variable penetrance or expression may
represent incomplete genotyping (Fig. 3), or that the
presumptive disease-causing role has erroneously
been assigned to a wrong gene and mutation. Al-
though functional studies are likely to elucidate the
role of the protein mutations, the speed of detection
of mutations will continue to outpace the experi-
ments that are needed to conﬁrm their functional
importance in the animal models or in vitro studies.
The approach to genetic testing could continue to be
either clinically guided, based on the sequencing of
genes selected on the basis of a clinical hypothesis, or
based on sequencing of large panels of disease-
associated/candidate genes (35–38). However, inter-
pretation of the results rather than performing the
test would pose a bigger challenge in the modern era
of next-generation sequencing.
On the basis of clinical and genetic evidence indi-
cating that most cardiomyopathies are familial dis-
eases and that genetic diagnosis is now reachable in a
high proportion of patients, scientiﬁc societies, such
as the Heart Rhythm Society, Heart Failure Society of
America, and the European Society of Cardiology,
have provided guidelines and recommendations for
family screening and genetic testing for cardiomy-
opathies (Table 2).
THE MOGE(S) NOMENCLATURE
In the quest for a genetic terminology, nomenclature
such as desmosomalopathy (39), cytoskeletalopathy
(40), sarcomyopathy (39), channelopathy (41), car-
diodystrophinopathy (42), cardiolaminopathy (43),
zaspopathy (44), myotilinopathy (45), dystrophin-
opathy (46), alpha-B crystallinopathy (44), desmin-
opathy (47), caveolinopathy (48), calpainopathy
(49), sarcoglycanopathy (50), dysferlinopathy (51),
merosinopathy (52), and emerinopathy (53) are being
used. Not only would such nosology evolve to be
unmanageable, the genetic notation would deﬁne
neither the phenotype nor the extent of systemic
involvement. For instance, labeling an arrhythmo-
genic cardiomyopathy as desmosomalopathy would
neither describe the clinical phenotype (right-sided,
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307biventricular, or predominantly left-sided cardio-
myopathy), nor describe the gene that causes the
cardiomyopathy. The zaspopathy may cause isolated
LVNC or dilated LVNC and may be associated with
skeletal myopathy (44). The troponinopathy may
result in hypertrophic, restrictive, or dilated pheno-
types. Hypertrophic myosinopathy may not distin-
guish between MYH7 and MYBPC3 or light chain
myosin. Even if these gene-speciﬁc terms are simply
added to the phenotype, the notations would
become unbearably complex, such as the arrhyth-
mogenic plakophillinopathy or desmocollinopathy,
dilated desmoplakinopathy or cardiolaminopathy,
hypertrophic myosinopathy or troponinopathy, and
restrictive desminopathy or troponinopathy.
Endorsed by the World Heart Federation, the
MOGE(S) classiﬁcation (54,55) was developed from the
need to describe cardiomyopathies by integrating a
morphofunctional phenotype-based description with
information regarding extracardiac organ invol-
vement and clinical (pattern of inheritance) andMD-AVBOHGADEG-LMNA [p.Arg190Trp] S (C-II)
Dilated cardiolaminopathy
FIGURE 1 Similar Phenotypes but Different Inheritance May Inﬂuenc
Mutations in genes coding for proteins of the nuclear envelope, such as
(DCM) with conduction disease. The phenotypes look alike (echocardiog
function in these 2 individuals), and the only distinguishing descriptor is
description below the echocardiograms). Both LMNA and EMD mutation
phosphokinase (sCPK) can be normal in both conditions; EMDmutations a
are associated with Autosomal dominant (AD) inheritance.molecular (disease gene and mutation) genetics in fa-
milial disease. The MOGE(S) classiﬁcation also aimed
at describing sporadic cardiomyopathies, and speci-
fying their etiology when known or unknown (Central
Illustration). Even for a sporadic cardiomyopathy, the
genetic origin of the disease cannot be excluded unless
a nongenetic cause is proven, and family screening is
completed to exclude familial inheritance. In the
absence of certainty, each cardiomyopathy would be
considered a potentially genetic disease, thus, offering
families the same screening options that would be
offered to an overt familial disease. In the past, pa-
tients with sporadic cardiomyopathy were frequently
labeled as nonfamilial, and diagnosed with chronic
(viral) myocarditis or peripartum cardiomyopathy.
Their long-term follow-up of families unfortunately
often uncovered a genetic etiology uponmanifestation
of the disease in offspring or siblings of the proband
with the same disease.
Borrowing from tumor, node, metastases (TNM)
staging in oncology (56), MOGE(S) nosology ofMD-AVBOHGX-LREG-EMD [p.Leu15Phe] S(B-II)
Dilated emerinopathy
e Comprehensive Assessment of the Family and Genetic Counseling
Lamin AC (LMNA) and Emerin (EMD) cause dilated cardiomyopathy
rams revealed DCM with similar left ventricular dimensions and
the type of inheritance (shown in blue letters in the MOGE[S]
s are pathologic and appear red in MOGE(S). Serum creatine
re associated with X-linked recessive inheritance and LMNAmutations
TNNI3 p.(Leu144Gln)
ID Phenotype Outcome Age (years)
I:1
I:4
II:1
II:2
II:3
II:5
II:6
II:7
II:8
II:10
III:3
III:5
III:7
III:8
III:14
III:15
III:2
IV:2
IV:3
IV:5
IV:9
V:1
V:2
V:3
V:4
V:6
VI:1
I:3
HCM
HCM
HCM
HCM
HCM
HCM
HCM
HCM
HCM
HCM
HCM/RCM
RCM
HCM
HCM
HCM
HCM
HCM
RCM
HCM
HCM
HCM
HCM/RCM
HCM
HCM
HCM
HCM
HCM
HCM
SD
SD
SD
SD
SD
SD
HF
HF
HF
HF
HF
HTX
SD
SD
SD
SD
SD
HTX
HTX
HTX
SD
SD
SD
SD
SD
SD
ICD
Death at
childbirth
53
32
65
56
45
60
50
47
69
67
64
56
8
32
32
14
14
41
56
28
41
25
17
32
14
25
17
16
MR OH GAD EG-TNNI3[p. Leu144GIn] SD-IV
MH+R OH GAD EG-TNNI3[p. Leu144GIn] SC-III
MH OH GAD EG-TNNI3[p. Leu144GIn] SC-III
FIGURE 2 The Same Genotype May Be Associated With Different
Phenotypic Expressions
Restrictive cardiomyopathy (RCM), hypertrophic cardiomyopathy (HCM)/RCM, and HCM
may occur in different family members who are carriers of the same mutation in TNNI3
(p.Leu144Gln). The table shows the ID (family member), age, phenotype, and outcome of
family members. The echocardiographic ﬁgures refer to cardiac phenotypes in 3 family
members indicated by the corresponding colors: RCM ¼ red-bordered ﬁgure (III:3);
HCM/RCM ¼ blue-bordered ﬁgure (IV:5); HCM = green-bordered ﬁgure (VI:1). HF ¼ heart
failure; HTx ¼ heart transplantation; ICD ¼ implantable cardioverter-deﬁbrillator;
SD ¼ sudden death.
Arbustini et al. J A C C V O L . 6 4 , N O . 3 , 2 0 1 4
MOGE(S) Classiﬁcation of Cardiomyopathy J U L Y 2 2 , 2 0 1 4 : 3 0 4 – 1 8
308cardiomyopathies addressed 5 attributes: the mor-
phofunctional phenotype (M), organ involvement (O),
genetic or familial inheritance pattern (G), and etio-
logical description (E) of genetic defect or non-
genetic underlying cause. The functional status (S),
using the ACC/AHA (A to D) stage and New York HeartAssociation (NYHA) (I to IV) functional classes was
also added. The “S” notation is especially useful
when mutation carriers are healthy, or if they dem-
onstrate imaging-veriﬁed early abnormalities sug-
gestive of cardiomyopathy.
M: MORPHO-FUNCTIONAL PHENOTYPE. The “M”
notation provides the clinical diagnosis, which cor-
responds to the description of the phenotype such as
MD (DCM), MH (HCM), MA (ARVC), MR (RCM), and MNC
(LVNC). This notation corresponds to the current
clinical classiﬁcation of cardiomyopathies. The ﬁrst
and commonly used clinical diagnosis is labeled as a
subscript to the “M.” HCM that evolves into dilated
congestive phenotype or HCM presenting with sig-
niﬁcant restrictive pattern can be described as MHþD
or MHþR (Figs. 2 and 4). Multiple other combinations
may be possible, such as MDþNC or MAþNC or MHþNC.
The “M” notation also carries key clinical red ﬂags
such as short PR interval (PR), WPW, or AVB, which
may be displayed as MH[PR], MH[WPW], or MD[AVB]. It
also may describe a nonspeciﬁc or noncoded pheno-
type (such as hypertrabeculation when criteria for
LVNC are not fulﬁlled; NS[Hypertrab]). Furthermore,
“M” allows for the description of early phenotypes.
For instance, conditions where diagnostic criteria for
the suspected clinical phenotype (such as DCM or
HCM) are not fulﬁlled but the imaging data indicate
an increased LV diameter and a borderline LV func-
tion (ME[D]), or a possible LV hypertrophy (ME[H]) in
carriers of the mutation that have caused the disease
in the family. Clinically-unaffected mutation carriers
are described as M0. When the information about the
cardiac phenotype is not available, such as in the
deceased relatives, the description is MNA. Overall,
the “M” notation is ﬂexible and suitable for any
clinical combination of disease phenotypes and clin-
ical traits.
O: THE INVOLVED ORGANS. The second descriptor is
the organ involvement, which can either be the heart
only (OH) or in combination with other organ systems,
such as skeletal muscle (OHþM), auditory system
(OHþA), kidney (OHþK), nervous system (OHþN), liver
(OHþLi), gastrointestinal system (OHþG), cutaneous
(OHþC), ocular or eyes (OHþE), respiratory or lung
(OHþLu), or mental retardation (OHþMR). Healthy mu-
tation carriers are described as O0, because the heart
is still clinically unaffected; it complements the M0
notation. The involvement of organs/systems other
than the heart allows for convenient recognition of
syndromes (Fig. 5). The simple combination of data
on cardiac phenotype and involvement of kidney,
liver, lung, or gastrointestinal system can usefully
restrict the ﬁeld of diagnostic hypotheses and can
MH+D OH GAD EG-MYH7[p.Val606Met]+LMNA[p. Asp254GIy] SC-II
FIGURE 3 The Presence of More Than 1 Genotype May Inﬂuence
the Phenotype
The ﬁgure shows a 39-year-old male patient who was initially diagnosed with
HCM but has evolved to a dilated phenotype while maintaining the left
ventricular (LV) hypertrophy, in New York Heart Association functional class II.
His recent echocardiogram demonstrated an LV end-diastolic volume of 150
ml, LV end-diastolic dimension of 55 mm, LV ejection fraction of 50%, LV
hypertrophy (22 mm), left atrial dilation, patent foramen ovale, moderate-
severe pulmonary arterial hypertension, and pericardial effusion. Patient
received cardiac resynchronization therapy/ICD implantation after resusci-
tated cardiac arrest. The disease was autosomal dominant and associated with
mutations in the MYH7 and in LMNA both coming from the maternal lineage.
The LMNA variant, however, is still to be considered a variant of unknown
signiﬁcance.
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309address focused genetic testing. Such combinations
also allow for easy recognition of syndromes.
G: GENETIC INHERITANCE. The third descriptor re-
presents genetic or familial inheritance as deduced
clinically by family pedigree and screening. The
inheritance includes autosomal dominant (GAD),
autosomal recessive (GAR), X-linked (GXL), X-linked
recessive (GXLR), or dominant (GXLD) or matrilineal
(GM) transmission. Patients who are the uniquely
affected members of the family with a documented
disease mutation are described as de novo (GDN) or as
having phenotypically sporadic (GS) cardiomyopathy.
The negative or unknown family history (GN or GU)
and the family history not investigated so far (G0) also
can be speciﬁed.
E: ETIOLOGY. The notation “E” includes a description
in 2 steps. The ﬁrst step informs the underlying cause
of the cardiomyopathy, whichmay be of genetic (EG) or
nongenetic cause. The latter needs to be addressed
individually as in the following paragraph; the non-
identiﬁable cause is also noted (EN). The second nota-
tion deﬁnes precise etiology. For example, the gene
mutation needs to be speciﬁed next to the EG, and
similarly, the cause of the underlying disease in
nongenetic cardiomyopathies also needs to be
explained.
In genetic cardiomyopathies, the disease gene and
mutation(s) can be added, such as in the case of HCM
(EG-MYH7[p. Arg403Glu]) or familial amyloidosis (EG-ATTR
[p.Val122Ile]). The “E” speciﬁcation may describe: family
members who are noncarriers of the mutation that
causes the disease in the family (EG-Neg), the obligate
carrier (EG-OC), or the obligate noncarrier (EG-ONC).
EG-NA indicates nonavailability of the genetic test.
After completion of the screening of all known dis-
ease genes in familial disease, genetically orphan
patients are labeled as negative: EG-N (genetic defect
not identiﬁed). EG-0 indicates that genetic testing was
not done or was not feasible for any reason. When
all members of a single family are described, the
MOGE(S) system highlights mutations that do not
fully segregate with the phenotype or are part of
incomplete genotyping (Fig. 6). The increasingly
complex genetics (>1 mutation in a single patient) call
for a comprehensive description of the genetic make-
up of the patients and families. The international
nomenclature of genetic variants may facilitate the
description (57); the in silico evaluation supports the
interpretation of the signiﬁcance of each variant (e.g.,
PolyPhen-2 [58] and SIFT [59]).
The large public databases, such as the National
Heart, Lung, and Blood Institute’s Exome Sequencing
Project (60), the 1,000 Genomes Project (61), andUniversal Mutation Database (62), provide data on
minor allele frequency (MAF). Finally, the studies on
families provide segregation data, and pathology
studies (Fig. 7) or in vitro systems may eventually
contribute to document the abnormal expression of
the mutated protein. The way of describing complex
genetics in MOGE(S) can take advantage of color
coding (app available online [63]), which provides the
immediate information about pathologic mutations
(red), genetic variants of unknown signiﬁcance (VUS)
(yellow/orange), or a single nucleotide polymorphism
(SNP) with some possible functional effects (green)
(Central Illustration).
In nongenetic cardiomyopathies, the etiology can be
described as viral (V) (the ﬁrst notation) adding the
virus (e.g., Coxsackie B3 virus [CB3], human cyto-
megalovirus [HCMV], or Epstein-Barr virus [EBV]
presented as EV-HCMV, EV-CB3, or EV-EBV) for the second
notation; the infectious, nonviral diseases (EI) may be
presented with further speciﬁcation of the infectious
agent whenever possible. When the myocarditis is the
proven cause of the myocardial disease (EM), the
second notation could specify the origin of myocar-
ditis, such as sarcoidosis (EM-Sarcoid) or noninfectious
giant cell myocarditis. An autoimmune etiology,
TABLE 2 Genetic Testing: Position of the Scientiﬁc Societies
Type of Cardiomyopathy Recommendation
Strength of
Evidence/Class
Heart Failure Society of America, 2009 (76)
All patients with
cardiomyopathy
Clinical screening for cardiomyopathy is recommended:
 In asymptomatic ﬁrst-degree relatives A
 In asymptomatic at-risk relatives who are known to carry the disease-causing mutation A
 In asymptomatic at-risk relatives when genetic testing has not been performed or has not identiﬁed a disease-causing mutation A
Clinical screening consists of history, physical examination, ECG, echocardiography, CK-MM, signal averaged ECG in ARVC only,
24-h Holter monitoring in HCM and ARVC, exercise treadmill testing in HCM, and CMR in ARVC
B
Clinical screening should be considered at scheduled follow-up intervals or at any time that signs and symptoms appear
At-risk ﬁrst-degree relatives with any abnormal clinical screening test (regardless the genotype) should be considered for repeat
clinical screening at 1 year
C
HCM Family history for $3 generations A
Clinical screening for cardiomyopathy in asymptomatic ﬁrst-degree relatives A
Genetic testing should be considered for the 1 most clearly affected person in a family to facilitate family screening and
management (MYH7, MYBPC3, TNNT2 TNNI3, TPMI, ACTC1, MYL2, and MYL3).
A
DCM Family history for $3 generations A
Clinical screening for cardiomyopathy in asymptomatic ﬁrst-degree relatives A
Genetic testing should be considered for the 1 most clearly affected person in a family to facilitate family screening and
management (LMNA, MYH7, TNNT2, SCN5A, DES, MYBPC3, TNNI3, TPMI, ACTC, PLN, LDB3, and TAZ)
B
RCM Family history for $3 generations B
Clinical screening for cardiomyopathy in asymptomatic ﬁrst-degree relatives B
Genetic testing should be considered for the 1 most clearly affected person in a family to facilitate family screening and
management (gene tests: uncertain)
C
ARVC Family history for $3 generations A
Clinical screening for cardiomyopathy in asymptomatic ﬁrst-degree relatives A
Genetic testing should be considered for the 1 most clearly affected person in a family to facilitate family screening and
management (DSP, PKP2, DSG2, and DSC2)
A
LVNC Family history for $3 generations A
Clinical screening for cardiomyopathy in asymptomatic ﬁrst-degree relatives B
Genetic testing should be considered for the 1 most clearly affected person in a family to facilitate family screening and
management (gene tests: uncertain)
C
CMP with extracardiac
traits
Family history for $3 generations A
Clinical screening for cardiomyopathy in asymptomatic ﬁrst-degree relatives A
Genetic testing should be considered for the 1 most clearly affected person in a family to facilitate family screening and
management
A
ESC Position Statement on Genetic Counseling and Testing in Cardiomyopathies, 2010 (16)
Diagnostic work-up
in patients and
families with CMP
(the numbers in
the right column
indicate the steps)
Genetic counseling 1
Information for patients and families: genetic origin, inheritance pattern and heritability, phenotype and age-dependence,
beneﬁts of clinical family screening, pregnancy-related risk, available genetic tests, and contacts with charities and referral
centers.
Clinical screening in relatives of probands with cardiomyopathy when genetic test is not available 2
First-degree relatives, unless a nongenetic cause of the disease is proven
Age for starting the ﬁrst screening and scheduled monitoring, based on age, type of cardiomyopathy, lifestyles, and symptoms
(family-tailored monitoring)
Clinical screening in asymptomatic relatives who carry a disease-causing mutation 3
Monitoring including ECG, ECHO, exercise test, 24-h Holter-ECG, and disease-speciﬁc clinical evaluations
Genetic testing and positive diagnosis 4
Appropriate for the diagnosis in special or atypical forms of cardiomyopathies, in the setting of expert teams after detailed
clinical and family assessment
Genetic testing and predictive diagnosis 5
Asymptomatic relatives when the disease-causing mutation has been previously identiﬁed in the family Appropriate
Post-mortem genetic tests: the deceased family member is the only affected in the family; appropriate in HCM and ARVC;
questionable in sporadic DCM and RCM
To be considered
In children, at the age at which cardiac examination is useful To be considered
Genetic testing and prognostic testing 6
Cannot be systematically recommended for prognostic stratiﬁcation Non systematic
In selected patients or for selected types of cardiomyopathies; the setting is of expert teams after clinical and family
assessment
To be considered
Genetic testing and pre-natal diagnosis 7
Continued on the next page
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TABLE 2 Continued
ESC Position Statement on Genetic Counseling and Testing in Cardiomyopathies, 2010 (16)
Legal rules for pre-natal diagnosis vary in different countries No standards
Selected disorders or high-risk situations in the setting of expert teams after detailed clinical and family assessment Appropriate
Molecular analyses and appropriate and correct interpretation 8
Should be performed in certiﬁed diagnostic laboratories; requires expert multidisciplinary centers Suggestion
Phenotype and family assessment should be available for appropriate tests and correct interpretation Suggestion
Post-test genetic counseling 9
Recommended for all patients and families (appropriate) with a cardiomyopathy Recommended
Should be performed by speciﬁcally-trained professionals, in a multidisciplinary manner, and in specialized centers Suggestion
HRS/EHRA, 2011 (77)
HCM Genetic test should be performed in patients with clinical diagnosis of HCM, either comprehensive or targeted
(MYBPC3, MYH7, TNNI3, TNNT2, TPM1)
I
Mutation-speciﬁc genetic testing in relatives of mutated probands I
DCM Diagnosis in probands/index patients with DCM with CCD, either comprehensive or targeted (LMNA and SCN5A) I
Mutation-speciﬁc genetic testing in relatives of mutated probands I
Patients with familial DCM: conﬁrm diagnosis; identify patients at risk of arrhythmias; and facilitate family screening
and monitoring plans
IIa
RCM Mutation-speciﬁc test in family members after identiﬁcation of the causative mutation in the index case. I
Patients with clinical suspicion for RCM IIb
ACM/ARVC Mutation-speciﬁc test in family members after identiﬁcation of the causative mutation in the index case. I
Comprehensive and targeted (DSC2, DSG2, DSP, JUP, PKP2, and TMEM43) for patients satisfying task force criteria
for ACM/ARVC.
IIa
Patients with 1 major or 2 minor criteria, according to the 2010 task force criteria IIb
Patients with only a single minor criterion III
LVNC Mutation-speciﬁc test in family members after identiﬁcation of the causative mutation in the index case. I
Patients with an established clinical diagnosis of LVNC IIb
The table summarizes the strength of evidence for genetic testing provided in existing documents from scientiﬁc societies with the caveat that randomized and/or blinded studies do not exist and published
data are either from a single institution or multicenter collections or registries.
ACM ¼ arrhythmogenic cardiomyopathy; ARVC ¼ arrhythmogenic right ventricular cardiomyopathy; CCD ¼ cardiac conduction disease; CK-MM ¼ creatine kinase-MM; CMR ¼ cardiac magnetic resonance;
DCM ¼ dilated cardiomyopathy; ECG ¼ electrocardiogram; ECHO ¼ echocardiogram; EHRA ¼ European Heart Rhythm Association; ESC ¼ European Society of Cardiology; HCM ¼ hypertrophic cardio-
myopathy; HRS ¼ Heart Rhythm Society; LVNC ¼ left ventricular noncompaction; RCM ¼ restrictive cardiomyopathy.
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311either suspected or proven (EAI-S or EA-P), may popu-
late the ﬁrst notation followed by the speciﬁc eti-
ology, such as rheumatoid arthritis or systemic
lupus erythematosus. The MOGE(S) app allows the
description of each proven diagnosis (e.g., MD
OHþCþS G0 EAI-P-Rheumatoid Arthritis SC-II or MD OHþC G0
EAI-P-Rheumatoid Arthritis SB-II). Nonheritable amyloid-
osis (EA-K, EA-L, or EA-SAA) represent kappa, lambda, or
serum amyloid A protein characterization, respec-
tively. Toxic cardiomyopathies, either endogenous,
such as pheochromocytoma-related cardiomyopathy,
or drug-induced cardiomyopathy, are described
(ET-Pheo or ET-Chloroquine). When the former is described
in the context of a syndrome (such as VHL, MEN2A/2B,
or NF1), the description can be implemented by adding
the name of the syndrome (i.e., ET-Pheo-VHL). The
Loefﬂer’s eosinophilic endomyocarditis can be de-
scribed according to the cause as either being id-
iopathic or a part of myeloproliferative disorder
associated with the somatic chromosomal rearrange-
ment of PDGFRa or PDGFRb genes that generate a
fusion gene encoding for constitutively active PDGFR
tyrosine kinases (64).S: FUNCTIONAL STATUS. “S,” in 2 notations, de-
scribes the heart failure ACC/AHA stage (A to D)
coupledwith NYHA functional class (I to IV), presented
as SA-I or SC-II, and so on. The descriptor “S” is optional,
but may come in handy for the description of early
cardiomyopathy. The ACC/AHA guidelines include
patients with a family history of cardiomyopathy in
stage A. In families with known mutation, the diag-
nosis of early cardiomyopathies can be further sup-
ported by the presence of the mutation(s), whereas in
genetically orphan familial cardiomyopathy, only the
early imaging markers of the disease can be high-
lighted. This description could be especially useful for
those individuals seeking a deﬁnitive recommenda-
tion from the physician about their sport worthiness.
Although criteria for early diagnosis of cardiomyopa-
thy are not systematically described, increasingly,
family screening and monitoring have revealed that
the cardiomyopathies likely serve a long pre-clinical or
subclinical course before the onset of symptoms or the
manifestation of the clinical phenotype (65).
The Central Illustration shows the MOGE(S)
system notations and modeling. The alphabetical
Proband’s 
cardiomyopathy
(CM) diagnosis
(DCM, HCM, RCM,
ARVC/D, LVNC)
Clinical history 
and evaluation
Functional
status
ACC/AHA,
NYHA
Multidisciplinary 
evaluation
according per
clinical needs
or diagnostic
hypothesis
Organ 
involvement:
Extracardiac 
organs/tissues
O
ORGAN/SYSTEM
INVOLVEMENT
G
GENETIC INHERITANCE
PATTERN
E
ETIOLOGY
S
STAGE
D Dilated 
H Hypertrophic 
R Restrictive
R EMF 
Endomyocardial
LV=left ventricle 
RV=right ventricle
RLV=biventricular
A ARVC 
M=major
m=minor
c=category
LV= left ventricle 
RV=right ventricle
RLV=biventricular
NC LVNC
E Early, with type 
in parentheses
NS 
phenotype
NA Information
non available
0 
H Heart
LV=left ventricle 
RV=right ventricle
RLV=biventricular
M Muscle (skeletal) 
N Nervous 
C Cutaneous
E Eye, Ocular 
A Auditory
K Kidney
G Gastrointestinal 
Li Liver
Lu Lung
S Skeletal
0 Absence of 
organ/system 
involvement*, 
e.g. in family 
members who 
are healthy 
mutation carriers; 
the mutation is 
inheritance in G
G Genetic cause
OC Obligate carrier
ONC Obligate non-carrier
DN De novo
Neg Genetic test negative for
the known familial mutation
N
0 No genetic test, any reason* 
G-A-TTR  Genetic amyloidosis 
G-HFE  Hemochromatosis 
Non-genetic etiologies:
M Myocarditis
V Viral infection (add the virus 
AI Autoimmune/immune-
mediate; suspected (AI-S), 
proven (AI-P)
A Amyloidosis (add type: 
A-K, A-L, A-SAA)
I Infectious, non viral 
(add the infectious agent)
T Toxicity (add cause/drug)
Eo Hypereosinophilic
heart disease
O Other
N Family history negative
U Family history unknown
AD Autosomal dominant
AR Autosomal recessive
XLD X-linked dominant
XLR  X-linked recessive
XL X-linked
M Matrilineal
0 Family history not investigated*
Undet Inheritance still undetermined
S  Phenotypically Sporadic
(apparent or real)
ACC-AHA
stage
represented 
as letter
A, B, C, D
NA 
not applicable
NU 
not used 
followed by
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represented
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I, II, III, IV
CH
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S
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CR
IP
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Clinical 
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relative
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Relatives
with ECG
and/or Echo
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Healthy family 
members 
with normal 
ECG and ECHO
Familial Non-familial;
Phenotypically
sporadic
Inheritance
AD, AR XL
(R or D) or
Matrilineal
Informative 
and non-
informative 
families
Consultant 
non-informed
about family
history
Genetic counseling
with pedigree
Genetic testing
in the proband
Positive
Cascade
genetic
testing in
relatives
Negative
Regular
monitoring
in relatives
New tests
novel 
genes
M
MORPHO-FUNCTIONAL
PHENOTYPENO
TA
TI
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CENTRAL ILLUSTRATION The MOGE(S) Nosology System for Classifying CM Patients
Evaluation of cardiomyopathy patients and development of MOGE(S) nosology. (M) The morphofunctional phenotype description may contain
more information using standard abbreviations: AVB ¼ atrioventricular block; LQT ¼ prolongation of the QT interval; YPR ¼ short PR interval;
YR ¼ low electrocardiographic voltages; WPW ¼ Wolf Parkinson White syndrome; and other clinical red ﬂags. These red ﬂags are to be placed
in parentheses after the notation of morphofunctional phenotype. Overlapping (HþR), (DþA), (NCþH), (HþD), (DþNC) or more complex
combinations such as (HþRþNC). *Notation is zero (0) not the letter “O.” (E) The etiologic annotation provides the description of the speciﬁc
disease gene and mutation, as well as a description of nongenetic etiology. Even when genetic analysis is not available, the (G) may inform
about a genetic disease, supporting family monitoring strategies. #According to the Human Genome Variation Society, genetic variants should
be classiﬁed based on their effects on gene function as: affecting function, probably affecting function, unknown (variants of unknown
signiﬁcance [VUS]), probably not affecting function, and not affecting function. A color code assigned to each variant can provide information
about the potential role of the identiﬁed variant: affects function or probably affects function (red); Variant of Unknown Signiﬁcance (VUS)
(yellow); and probably does not affect function (or probably no functional effect) or does not affect function (no functional effect)
(green). The compilation is guided by the MOGES app (63). ACC ¼ American College of Cardiology; AHA ¼ American Heart Association;
ARVC/D ¼ arrhythmogenic right ventricular cardiomyopathy/dysplasia; DCM ¼ dilated cardiomyopathy; ECG ¼ electrocardiogram;
ECHO ¼ echocardiogram; HCM ¼ hypertrophic cardiomyopathy; LVNC ¼ left ventricular noncompaction; NYHA ¼ New York Heart Association;
RCM ¼ restrictive cardiomyopathy.
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312components are likely going to change in parallel
with new scientiﬁc information. The proposed
nomenclature reﬂects the current diagnostic work-
up of cardiomyopathies for evaluation of the
phenotype, family screening, and genetic testing inthe Sanger and post-Sanger era. To facilitate the
application and to provide a simple summary for
the patient’s clinical record by the MOGE(S) system,
we encourage the use of the web-assisted app (63),
which can be downloaded for smartphones and
MH+R OH GDN EG-MYL6[p.Gly162Arg] SD-IV
FIGURE 4 Variation in Phenotypic Expression
The hypertrophic cardiomyopathy (HCM) phenotype with restrictive pattern may be caused
by defects of sarcomere genes, including less common genes, such as MYL6, that code the
myosin light chain 6 protein. The echocardiogram is from a 12-year-old girl waiting for
heart transplantation, in New York Heart Association functional class IV, who genetically
showed a de novo mutation. The echocardiogram shows normal left ventricular (LV)
end-diastolic volume, borderline systolic LV dysfunction (ejection fraction ¼ 50%), sig-
niﬁcant diastolic dysfunction, mild LV hypertrophy (interventricular septum ¼ 12 mm),
severe biatrial dilation (right > left), mild right ventricular dysfunction, tricuspid regur-
gitation, mild pulmonary hypertension (40 mm Hg), and pericardial effusion.
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313tablets and can be ﬂexibly edited, expanded, or
modiﬁed.
FLEXIBILITY AND EXPANDIBILITY
OF MOGE(S) SYSTEM
Similar to the TNM staging system, MOGE(S) allows
ﬂexibility and can be expanded when needed. The
authors believe that the nomenclature will evolve to
become more comprehensive and user-friendly as
clinicians begin to apply it in practice. Investigators
from around the world have suggested modiﬁcations
in MOGE(S) nosology (66,67), such as in ARVC/
arrhythmogenic ventricular cardiomyopathy and
EMF. The diagnostic criteria for ARVC have been
debated and modiﬁed, and the MA notation can be
further speciﬁed with the help of the major [M] or
minor [m] diagnostic clues that are variably combined
in the Modiﬁed Task Force Criteria (68). These criteria
deﬁne ARVC as deﬁnite when 2 major [M2], 1 major
and 2 minor [M1þm2], or 4 minor criteria from 4
different categories [m4X4] are present; borderline
when 1 major and 1 minor [M1þm1] or 3 minor criteria
from different categories [m3X3] are present; and
possible when 1 major or 2 minor criteria from
different categories [M1þm2X2] are present. The
number of the major and minor criteria can be added
to the main MA notation. A deﬁnite diagnosis may be
described as MA[M2], MA[M1þm2X2], or MA[m4X4]; a
borderline diagnosis as MA[M1þm1] or MA[m3X3]; and a
possible diagnosis as MA[M1] or MA[m2x2]. The “M”
notation can therefore summarize not only the diag-
nosis or diagnostic hypothesis but also the strength of
the diagnosis (69).
A recent commentary appropriately emphasized the
need for morphological notation for important car-
diomyopathies from low- and middle-income coun-
tries, such as tropical endomyocardial ﬁbrosis (EMF)
(67), which is one of the most prevalent causes of
restrictive cardiomyopathy (70). Because EMF can
manifest as isolated or dominant LV EMF, isolated or
dominant right ventricular EMF, or biventricular (right
ventricular þ LV) EMF, MOGE(S) can describe the dis-
ease as well as the single or double ventricular
involvement (64).
A possible limitation of the MOGE(S) nosology is
the lack of information about 1 of the most important
clinical issues in cardiomyopathies: arrhythmias.
As anticipated (54,55), the classiﬁcation of arrhyth-
mias is far from the aim of MOGE(S); however, we
have received overwhelming suggestions for expan-
sion of the “S” notation to include the information
about rhythm disturbances in cardiomyopathies that
would give the clinical advantage of highlightingpatients deserving of a device implantation for ar-
rhythmias. The MOGE(S) committee is working with
electrophysiologists to develop a clinically-useful fast
rhythm disturbances description as a third “S”
notation.
MOGE(S) IN DAY-TO-DAY
CLINICAL PRACTICE
Upon the ﬁrst reading, MOGE(S) may appear to be a
complex nosology system that further complicates
the description of cardiomyopathies. However, in
practice, it is rather simple to apply and the use of the
app provides a guided step-by-step compilation. The
use of MOGE(S) does not obligate a clinician to
include genetic testing. As presented in the Central
Illustration, the genetic tests may not be available or
feasible. However, it behooves clinicians to make an
effort to elicit family history, especially about sudden
death, and document familial patterns. MOGE(S)
offers a hierarchical (Phenotype/Organ/tissue In-
volvement/Genetic /familial/Etiology/gene) but
ﬂexible structure that readily provides several
descriptors in a standardized language. This system
also necessitates the routine diagnostic work-up
for cardiomyopathies in probands and relatives.
Whether or not all information queried by MOGE(S) is
Mitochondrial Cardiomyopathy
MH+D (WPW) OH+M+N+E+A GM EG-MTDNA[A3243G]
FIGURE 5 HCM Phenocopy
The ﬁgure shows an LV hypertrophy associated with a mitochondrial DNA mutation that evolves into dilated phenotype. The multiorgan
involvement clariﬁes the syndrome. MOGE(S) describes the type of cardiomyopathy (HþD) and the involvement of skeletal muscle, ocular, and
auditory systems, as well as the nervous system. The ﬁgure shows the electrocardiographic and echocardiographic features of a typical
mitochondrial cardiomyopathy. Electrocardiogram and echocardiogram both show evidence of LV hypertrophy; electrocardiogram also shows
Wolff-Parkinson-White syndrome pre-excitation. HCM evolves though LV dilation and dysfunction; in the present case the ejection fraction was
30%. The cryptogenic stroke was the cause of death in this patient.
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314immediately available does not hamper its applica-
tion. In day-to-day practice, MOGE(S) can be applied
at the bedside, and collected data can be easily sub-
mitted to repositories. In a discharge summary, the
concluding diagnosis “Dilated Cardiomyopathy (MD
OH GAD EG-MYH7[Ile533Asn] SB-II)” may provide compre-
hensive information about the patient. For instance,
after a family screening, the mutation does not
segregate or a second mutation is identiﬁed. In that
case, MOGE(S) allows the description of new infor-
mation (MD OH GAD EG-MYH7[Ile533Asn]þMYBPC3[Arg326Gln]).
(S) is a dynamic notation that may modify during
follow-up, and its use can provide information about
change in the functional status and evolution of
remodeling status. Although NYHA functional class is
universally used, ACC/AHA stage has been less
commonly applied in clinics. It can be difﬁcult to
apply to cardiomyopathies, such as classical ARVC,
especially when diagnosed on 2 major criteria such as
major ECG changes (e.g., negative T waves in v1 to v3)
and sudden cardiac death or a ﬁrst-degree relative or
a known pathologic mutation. MOGE(S), however,
does not obligate us to ﬁll all ﬁelds, and the MOGE(S)App 2 includes the possibility of selecting “ACC-AHA
not used” when not applied or applicable.
The following are a few examples from our data-
base pertaining to the application of MOGE(S):
 “MD OHþM GAD EG-NA SC-III” represents a baseline
description of the patient (II:1) who was diagnosed
with DCM, presenting with both cardiac and mus-
cle involvement. He was a member of a family with
the autosomal dominant DCM, but the genetic
testing was not available. The functional status
was described as ACC/AHA stage C and NYHA
functional class III. Subsequently, when the ge-
netic information became available, the notation
was changed to “MD OHþM GAD EG-LMNA[p.Arg190Trp]
SC-III.” During follow-up, after starting the treat-
ment with an improvement in the NYHA functional
class, the functional status changed to “MD OHþM
GAD EG-LMNA[p.Arg190Trp] SC-I.” At echocardiographic
evaluation a brother (II:3) of the proband showed
LV dilation, and borderline LV ejection fraction: he
was described as “ME[D] OH GAD EG-NA SB.” Further
in the course of the follow-up, the description was
Family member
I:2
I:1
II:1
II:2
II:3
II:4
II:5
III:1
III:2
III:3
IV:1
IV:2
IV:4
V:1
MOGES
MOOOGUEG-O
MOOOGUEG-O
MOOOGUEG-O
MOOOGUEG-O
M0O0GUEG-0
M0O0GUEG-(OC)
M0O0GUEG-NegSA-I
M0O0GUEG-NegSA-I
M0O0GADEG-NegSA-I
M0O0GADEG-OSA-I
M0O0GUEG-O
MHOHGUEG-MYBPC3 [IVS16-1G>A]SA-I
MOOOGADEG-MYBPC3 [IVS16-1G>A]SA-I
MHOHGUEG-(OC)
I:1
II:1 II:2 II:3 II:4 II:5
III:1 III:2 III:3
V:1
IV:2 IV:3 IV:4
AF, stroke
Age: 59 years
Genetic test: not done
AF
Age: 90 years
Genetic test: negative
HCM, LVT=18mm
Onset: 30 years
Death:37 years
Genetic test: NA
HCM LVT=16mm
Onset: 52 yrs
Age=56 years
Genetic test: Positive
LVT=8mm
Age=36 years
Genetic test: IV:1
positive
LVT=8mm
Age=24 years
Genetic test:
negative
LVT=9mm
Age: 56
years
Genetic test:
Negative
I:2
FIGURE 6 Variable Penetrance and Mutation Segregation With Phenotype
The proband (arrow) is a carrier of a MYBPC3 (IVS16-1A>G) mutation that is known to be associated with hypertrophic cardiomyopathy (HCM).
Her brother (obligate carrier) was affected by the age of 30 years. The niece (daughter of the brother) is a carrier of the mutation and healthy at
the age of 36 years, with a maximal left ventricular thickness (LVT) of 8 mm. Although the penetrance can be variable and late, the mutation
does not seem to segregate with the phenotype by age. AF ¼ atrial ﬁbrillation.
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315completed as “ME[D] OH GAD EG-LMNA[p.Arg190Trp]
SB-I.” He was classiﬁed as stage B-I due to asymp-
tomatic myocardial involvement. Another brother
(II:2) underwent genetic testing and an echocar-
diographic examination and tested positive to
the genetic screening but echocardiogram was
entirely normal. He was described as “M0 O0 GAD
EG-LMNA[p.Arg190Trp] SA-I.” (Online Fig. 1 shows the
family pedigree at the end of the family screening.)
 “MD OHþMþNþA GM EG-MtDNA [tRNALeu A3243G] þ GJB2
[del30G hetero] SD-IV” describes a patient (II:3) admitted
with severe DCM, with involvement of the skeletal
muscle, prior stroke, hearing loss, a positivematernal family history for loss of hearing, and
diabetes. The “O” notation in this case offers an
instant suspicion of a known pathologic mutation in
mitochondrial deoxyribonucleic acid (MtDNA).
She also was a carrier of the heterozygous GJB2
del30G that, when homozygous, causes hearing
loss. Two sisters showed hearing loss and diabetes.
The phenotype of the proband was severe, as
described by the functional status (ACC/AHA stage
C, NYHA functional class IV). We could not trace
reports of the early phase of the cardiomyopathy
that could theoretically have been HCM in origin
(Online Fig. 2).
AC
B
D
MD(>sCPK)OH+MGX-LREG-DYS[Del45-48] SC-II
MD(AVB)OHGADEG-LMNA[p.Arg190Trp] SB-I
FIGURE 7 Genotypic Expression May Play a Role in Arrhythmogenicity
When tissue samples are available, such as in endomyocardial biopsies or fromhearts excised
during transplantation, the expression of the mutated proteins can be investigated either
for diagnosis (Dystrophin) or for supporting the diagnostic hypothesis and investigating
the effects of the mutations (i.e., Lamin AC). The 2 sets of the immunohistochemically-
stained histomicrographs refer to patients with either dilated cardiolaminopathy (top)
or dilated cardiodystrophinopathy (bottom). The endomyocardial biopsy above shows
decreased expression of the protein (B) compared with the normal control sample (A).
The MOGE(S) describes the clinical and genetic status. Below, the endomyocardial biopsy
from the patient with dilated cardiodystrophinopathy (D) with multifocal loss of
protein expression as typically observed in heart of patients with dystrophin defects,
versus normal control sample (C). The MOGE(S) describes the clinical and genetic
status of the patient. The cardiolaminopathy patient with mildly-normal left ventricular
(LV) systolic function has demonstrated life-threatening tachyarrhythmias. However,
the dystrophinopathy patient with large LV dimensions and severely depressed LV
ejection fraction did not require implantable cardioverter-deﬁbrillator intervention
for 2 years.
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316 “MAþHypertrab OH GUndet EG-LDB3 [p.Thr507Asn] þ DSG2
[p.Lys479Glu] SB-II-III” describes a patient (II:1) diag-
nosed with ARVC and hypertrabeculation, exclu-
sive involvement of the heart, without a positive
family history; likely, but still not proven, a
recessive disease. In this patient, we identiﬁed 2
variants of uncertain signiﬁcance (VUS, yellow-
orange color in the MOGES app) of biparental
origin in 2 different genes. To date, the probandis the only affected member of the family; the
young daughter also carries the 2 variants and is
healthy, only showing increased trabeculation of
the LV apex. The phenotype in the proband is
severe as described by the functional status (ACC/
AHA stage C, NYHA functional class II to III)
(Online Fig. 3).
 “MH OH GAD EG-MYBPC3[IVS16-1G>A] SB-II” describes a
patient (III:3) diagnosed with HCM, exclusive
involvement of the heart, with a positive family
history in which the disease is inherited as an
autosomal dominant trait, and caused by a known
mutation in MYBPC3. The functional status is
described by the ACC/AHA stage B, NYHA func-
tional class II. After family screening, her daughter
was found to be unaffected and to not be a carrier
of the mutation identiﬁed in the proband (M0 O0
GAD EG-Neg). The sister also was not affected, but
was a carrier of the mutation identiﬁed in the
proband (M0 O0 GAD EG-MYBPC3[IVS16-1G>A] SA-I). Her
niece, daughter of the affected brother (who died
without genetic testing), was not affected but was
a carrier of the mutation identiﬁed in the proband.
This simple information describes her father as the
obligate carrier of the mutation. The evaluation of
the niece, however, presented the problem of
nonsegregation of the genotype with the phenotype
by age. She showed amaximal LV thickness of 8 mm
by the age of 36 years, whereas her father was
affected by the age of 30 years (Fig. 6).
 “MR OHþMþNþLi GN EG DN-LAMP2 [p.His260Pro fs22] SC-II”
describes a patient diagnosed with RCM, along
with associated myopathy, cognitive impairment,
and liver disease. The patient had a negative family
history and screening. He was found to carry a
frame-shift mutation in the LAMP2 gene; the
mutation was absent in both parents. The car-
diomyopathy was rather severe at onset, with ar-
rhythmias and advanced LV function impairment
(Online Fig. 4).
CONCLUSIONS
A substantial increase in the knowledge of the genetic
bases of cardiomyopathy calls for a standardized,
universally acceptable classiﬁcation/nosology system
that integrates phenotype description as well as
genetic information. The ﬂexible MOGE(S) system
facilitates the transition of description of cardiomy-
opathies from the pre-genetic to the genetic era and
ensures the capture of an enormous amount of
data that could be lost if not systematically regis-
tered. The use of the MOGES app obligates descrip-
tion of the results achieved in all diagnostic steps,
J A C C V O L . 6 4 , N O . 3 , 2 0 1 4 Arbustini et al.
J U L Y 2 2 , 2 0 1 4 : 3 0 4 – 1 8 MOGE(S) Classiﬁcation of Cardiomyopathy
317including clinical cardiologic evaluation, extra-
cardiac evaluation, clinical genetics, family screen-
ing, molecular genetics when possible, and functional
status. This exercise provides uniform language and
easy-to-capture identical information for data mining
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